@entity3925 in the Prevention of XXXX in @entity1 with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET @entity955 Trial and Its Subanalyses.

@entity1 @entity64 @entity510 @entity177 @entity887 @entity3925 @entity955 @entity1011 @entity360 @entity1229
UNASSIGNED: @entity955 ( @entity955 ) is an increasingly common cause of @entity64 and systemic @entity887 . While @entity1229 has been the mainstay of @entity64 prevention in @entity1 with @entity955 , newer novel oral anticoagulant medications are now available. @entity3925 , a direct factor Xa inhibitor with a rapid onset and offset after oral administration, offers potential advantages over @entity1229 , predominantly due to its predictable pharmacokinetics across wide @entity1 populations. It requires no coagulation monitoring, and only two different doses are needed (20  mg daily for @entity1 with normal renal function and 15  mg daily in those with @entity177 ). A large randomized trial (ROCKET @entity955 ) has shown non-inferiority to @entity1229 for preventing @entity64 or systemic @entity887 in the per-protocol population and superiority to @entity1229 in the on-treatment safety population. Several subanalyses confirm that the treatment effect of @entity3925 is consistent across different @entity1 subgroups, including those with @entity177 . The tolerability of @entity3925 appears similar to that of @entity1229 , with comparable overall bleeding rates in clinical trials. In ROCKET @entity955 , significantly lower rates of fatal and @entity510 were seen with @entity3925 , while lower rates of @entity360 were seen with @entity1229 . Important contraindications to @entity3925 include valvular @entity955 , the presence of a prosthetic valve (mechanical or bioprosthetic) or valve repair, the need for concurrent dual antiplatelet therapy, and @entity1011 clearance <30  ml/min. Once-daily dosing and the lack of coagulation monitoring may increase utilization and adherence compared with @entity1229 , potentially decreasing the large burden of care associated with @entity64 secondary to @entity955 . Overall, @entity3925 offers a useful alternative to @entity1229 for @entity64 prevention in @entity1 with @entity955 .
